Physics:Tebideutorexant
Tebideutorexant[1] (developmental code names JNJ-61393215, JNJ-3215) is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders.[2][3][4][5] The drug was originated and developed by Janssen Pharmaceuticals.[2]
It is an orally active compound and acts as a selective antagonist of the orexin OX1 receptor (1-SORA).[3][4][5] Preliminary clinical findings suggest that tebideutorexant may have anti-panic effects in humans.[3][4] The elimination half-life of tebideutorexant is 13.6 to 24.6 hours.[6]
As of June 2023, tebideutorexant is in phase 2 clinical trials for the treatment of major depressive disorder while no further development has been reported for treatment of panic disorder and other anxiety disorders.[2] In 2025, a phase 2a, double-blind, placebo-controlled trial in adults with major depressive disorder and anxious distress found that adjunctive tebideutorexant did not significantly improve depressive symptoms on the Hamilton Rating Scale for Depression or anxiety on the Hamilton Anxiety Rating Scale compared with placebo.[7]
See also
- List of investigational antidepressants § Orexin receptor antagonists
- List of investigational anxiolytics
References
- ↑ PubChem. "Tebideutorexant" (in en). https://pubchem.ncbi.nlm.nih.gov/compound/Tebideutorexant.
- ↑ 2.0 2.1 2.2 "JNJ 61393215 - AdisInsight". https://adisinsight.springer.com/drugs/800045658.
- ↑ 3.0 3.1 3.2 "Experimental Drugs for Panic Disorder: An Updated Systematic Review". Journal of Experimental Pharmacology 13: 441–459. 2021. doi:10.2147/JEP.S261403. PMID 33889031.
- ↑ 4.0 4.1 4.2 "Hypocretins (orexins): The ultimate translational neuropeptides". Journal of Internal Medicine 291 (5): 533–556. May 2022. doi:10.1111/joim.13406. PMID 35043499.
- ↑ 5.0 5.1 "Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans". Translational Psychiatry 10 (1). September 2020. doi:10.1038/s41398-020-00937-9. PMID 32895369.
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedBrooks_2023 - ↑ "Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a study". European Neuropsychopharmacology 95: 14–23. June 2025. doi:10.1016/j.euroneuro.2025.03.007. PMID 40215570.
 |  |
